GLP-1 'summer body' claims: what med spas aren't telling you

What did @labelleviemedspa actually say?

Honestly? Almost nothing. The entire transcript is a repeating loop of "oh my" with no medical claims, no product names, no dosing information, and no explanation of what the video is actually showing. The caption does the heavy lifting here: "Summer bodies are made here" paired with hashtags like #medicalweightloss and #glp1 implies this is a promotion for GLP-1 receptor agonist therapy at their med spa.

The video is categorized under GLP-1 medications, which include semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide. Without seeing the visual content, the audio alone gives us essentially zero checkable medical claims. What we can fact-check is what the framing implies: that GLP-1 therapy produces "summer bodies" and that a med spa is an appropriate place to get it.

Does the science back this up?

GLP-1 receptor agonists do produce significant weight loss in clinical trials, but "summer body" framing oversimplifies what these medications actually do and who they are appropriate for.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed semaglutide 2.4mg produced an average 14.9% body weight reduction over 68 weeks in adults with obesity or overweight with weight-related conditions. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide produced up to 22.5% weight reduction at the highest dose.

Those are real, clinically meaningful results. But they come with real conditions: these are prescription medications, they require medical supervision, side effects include nausea, vomiting, and pancreatitis risk, and weight typically returns after stopping the medication (Wilding et al., 2022, Diabetes, Obesity and Metabolism). "Summer body" implies a seasonal cosmetic fix, which is not what the clinical evidence describes.

What did they get wrong (or right)?

They did not technically get anything wrong in the transcript because they said nothing specific. That is its own problem. Vague, hype-driven content about weight loss medications directed at a general social media audience carries real risks even without explicit false claims.

The "summer body" framing is the issue. It positions a medication class that was developed to treat chronic obesity and type 2 diabetes as a cosmetic seasonal product. The FDA approved Wegovy specifically for chronic weight management in adults with a BMI of 30 or higher, or 27 with a weight-related condition. Marketing this category of drug to anyone scrolling TikTok for summer fitness content blurs those boundaries considerably.

• What they likely got right: GLP-1 medications do produce weight loss when combined with lifestyle changes.
• What is missing: any mention of eligibility, risks, contraindications, or the difference between compounded and brand-name formulations.
• What is problematic: the implication that weight loss results are predictable, cosmetic, and accessible to anyone.

What should you actually know?

If you are considering GLP-1 therapy after seeing content like this, there are things you need to understand that this video does not tell you.

First, these are not interchangeable products. Compounded semaglutide, which many med spas dispense, is not the same as FDA-approved Wegovy or Ozempic. The FDA has explicitly warned consumers about compounded GLP-1 medications citing safety and quality concerns (FDA Drug Safety Communication, 2023). Compounded versions are not FDA-approved and have not gone through the same manufacturing standards.

Second, results vary significantly. The averages from clinical trials come from tightly controlled studies. Real-world outcomes, particularly through med spas with variable oversight, may look different. A 2023 analysis in JAMA Internal Medicine noted significant variation in prescribing practices and follow-up protocols outside of structured clinical settings.

Third, stopping the medication typically means weight returns. This is not a one-summer solution. Christensen et al. (2022, Diabetes, Obesity and Metabolism) found participants regained two-thirds of lost weight within one year of stopping semaglutide. Anyone entering this treatment should understand it may be a long-term commitment, not a seasonal one.